60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
0.5462
-0.0487 (-8.19%)
At close: Nov 9, 2026, 4:00 PM EST
0.5311
-0.0151 (-2.76%)
After-hours: Nov 9, 2026, 7:43 PM EST
60 Degrees Pharmaceuticals Employees
60 Degrees Pharmaceuticals had 3 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes 60 Degrees Pharmaceuticals the 43,009th largest employer in the world and 6,970th in the United States.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$404,977
Profits / Employee
-$2,874,812
Market Cap
1.92M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3 | 0 | - |
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Enlivex | 34 |
| VivoSim Labs | 15 |
| BioRestorative Therapies | 14 |
| Genprex | 13 |
| Revelation Biosciences | 9 |
| Kairos Pharma | 4 |
| XORTX Therapeutics | 3 |
SXTP News
- 12 days ago - 60 Degrees expands vector-borne disease research portfolio with USM - TheFly
- 12 days ago - 60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome - GlobeNewsWire
- 13 days ago - 60 Degrees’ tafenoquine shows improvement in all five babesiosis patients - TheFly
- 13 days ago - 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Transcript: Study update - Transcripts
- 4 weeks ago - 60 Degrees Pharmaceuticals Press release: Study update - Filings
- 4 weeks ago - 60 Degrees Pharmaceuticals to conclude enrollment in tafenoquine study - TheFly
- 4 weeks ago - 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA - GlobeNewsWire